Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nihon Chouzai, Matsumotokiyoshi to Ally to Open More Drugstores with Dispensing Services
November 10, 2008
- JT: Milestones Help Improve Pharmaceutical Business
November 10, 2008
- Council Recommends Early Approval of Intracranial Stent and Artificial Jaw Joint
November 10, 2008
- Torii: Business Hit by Generics of Futhan
November 10, 2008
- Eiken Chemical: Sales Up 2.9% but Full-year Profits Forecasts Revised Downward
November 10, 2008
- BUSINESS NEWS IN BRIEF
November 10, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 10, 2008
- Nippon Chemiphar: Sharp Drop in Profits Despite 5.8% Increase in Sales
November 10, 2008
- Colorectal Cancer Management GL to Be Revised in July 2009
November 10, 2008
- PMDA to Conduct More On-site Inspections Overseas for Generics
November 10, 2008
- GL in Preparation for Safer HRT
November 10, 2008
- COMMENTARY／Will World's Top Generic Maker Be Able to Succeed in Japan?
November 10, 2008
- IFN Markedly Effective against Hepatitis C when Continued for 72 Weeks
November 10, 2008
- 3 NMEs Recommended for Approval
November 10, 2008
- Hospital-GP Cooperation Important in Treating Hepatitis C
November 10, 2008
- Takeda Applies for Actos/Metformin Combination in Japan
November 10, 2008
- Revatio Shows Great Promise as Treatment for PAH
November 10, 2008
- Development in Japan Terminated or Suspended for 23 Drugs due to Difficulty Recovering Investment
November 10, 2008
- Takeda: Sales Up 13.9% with Highest-Ever Semiannual Sales
November 10, 2008
- Roche to Do at Least One Japan Deal per Year: Dr Zabrowski
November 10, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…